Clinical research regulation in India-history, development, initiatives, challenges and controversies: Still long way to go by Mohammed Imran, Abul K Najmi, Mohammad F Rashid, Shams Tabrez, Mushtaq A Shah

“…However due to casual approach in marketing approval for sale of the drugs, the unethical steps taken by some pharmaceutical companies and medical practitioners has reiterated the need to get appropriate understanding of present regulation of drugs and clinical research especially regarding the practical rules and regulations.…”
Get full text

What Do Nurses Think About the Immunization Campaign in Russia and the Prospects for the COVID-19 Pandemic Development? by O.S. Deyneka, A.A. Maksimenko

“…Most of the nurses surveyed believe that COVID-19 will never go away and that the media will support the epidemiological panic as it benefits the authorities and pharmaceutical companies.</p>…”
Get full text

Manufacturers’ views on outcome-based agreements by Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Lonneke Timmers, Anke Pisters-van Roy, Joël Gijzen, Nicole M.A. Blijlevens, Haiko Bloemendal

“…Methods: Dutch market-access experts from eight major pharmaceutical companies, globally active in the field of oncology, were interviewed. …”
Get full text

Bacterial Appraisal in Expired and Unexpired Pharmaceutical Products by Rida Inam, Hira Batool

“…It revealed that quality of unexpired products have to be improved by producers to minimize the bio-liability so pharmaceutical companies should adopt good manufacturing practice to avoid microbial contamination in unexpired pharmaceuticals as well as the consumer should be educated and are aware of hazardous effect of using expired products.…”
Get full text

Structural insights and clinical advances in small-molecule inhibitors targeting TGF-β receptor I by Carlota Leonardo-Sousa, Rodrigo Barriga, Helena F. Florindo, Rita C. Acúrcio, Rita C. Guedes

“…Our investigation extends to the patent literature, summarizing over 2 decades of innovation from leading pharmaceutical companies, spanning January 2000–May 2024. This consolidated structural and biochemical knowledge aims to facilitate the design of next-generation TGF-βRI inhibitors, addressing unmet clinical needs in oncology and fibrosis treatment. …”
Get full text

Targeting brain-health from "cradle to grave": Can we prevent or delay dementia? by Bhaskara P. Shelley

“…For a number of decades, clinicians, researchers, and pharmaceutical companies have laid emphasis on the development of a drug armamentarium for fighting dementia. …”
Get full text

Study of the seasonal dynamics tendencies of sales of substitution therapy medications for dry-eye syndrome treatment in Ukraine by Yu.O. Tomashevska, O.V. Kryvoviaz, O.V. Makarenko, V.M. Koval

“…The information received in the course of the study is necessary both for the patients and the employees of pharmaceutical companies engaged in wholesale and retail sales of medicines and medical devices. …”
Get full text

The Data Divide in Pharma: A Comparative Case Study of Business Analytics Capabilities Impact on Performance by Perdamen Sagala, Meditya Wasesa, Yos Sunitiyoso

“…Through comparative case studies of two affiliate offices of top global pharmaceutical companies in Indonesia, we employ open, axial, and selective coding to identify the key concepts and constructs influencing the relationship between BA capabilities and business performance. …”
Get full text

Application of Artificial Neural Networks to Predict the Intrinsic Solubility of Drug-Like Molecules by Elena M. Tosca, Roberta Bartolucci, Paolo Magni

“…Machine learning (ML) approaches are receiving increasing attention from pharmaceutical companies and regulatory agencies, given their ability to mine knowledge from available data. …”
Get full text

A Nexus between Working Capital Management and Profitability: A Case Study of Pharmaceutical Sector in Pakistan by Zeeshan Ahmed, Muhammad Zahid Awan, Muhammad Zulqarnain Safdar, Tafakhar Hasnain, Muhammad Kamran

“…The data utilized in this study is extracted from the annual reports of Pharmaceutical companies quoted in Karachi Stock Exchange (KSE). …”
Get full text

Nexus among green marketing practice, leadership commitment, environmental consciousness, and environmental performance in Jordanian pharmaceutical sector by Amro Alzghoul, Khaled M. Aboalganam, Omar Al-Kasasbeh

“…By employing a quantitative research methodology, this study provides valuable insights into the interaction of variables through the collection of empirical data from 11 pharmaceutical companies. Through an online survey, we obtained 287 responses by employing a random sampling technique. …”
Get full text

Definition of medical error and physicians’ interest in changes in the law by Renata Husarz, Anna Jurek, Janusz Jaroszyński, Marzena Furtak-Niczyporuk, Aneta Mela

“…The majority of doubts, which results from the obtained research, raises the issue of provision of medical help without the consent of the patient and the right to refuse treatment, but above all, what is quite surprising is the question of accepting gifts from pharmaceutical companies. The most frequently cited reasons influencing the lack of updating legal knowledge in the field of the performed profession were lack of time and a large number of duties, whereas the research group, in order to deepen their knowledge on that matter, most frequently used the Internet resources, industry articles, and on the third place was the training related to the subject matter of the medical law.…”
Get full text

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet by Mehta R, Piscitelli J, Wolstenholme A, Fu C, Crauwels H, Wynne B, Adkison K

“…Rashmi Mehta,1 Joseph Piscitelli,2 Allen Wolstenholme,3 Caifeng Fu,4 Herta Crauwels,5 Brian Wynne,6 Kimberly Adkison7 1GlaxoSmithKline, Research Triangle Park, NC, USA; 2UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA; 3GlaxoSmithKline, Collegeville, PA, USA; 4PAREXEL International, Durham, NC, USA; 5Janssen Pharmaceutical Companies, Beerse, Belgium; 6ViiV Healthcare, Collegeville, PA, USA; 7ViiV Healthcare, Research Triangle Park, NC, USACorrespondence: Kimberly AdkisonViiV Healthcare, 5 Moore Drive, Research Triangle Park, NC 27709, USATel +1 919 483-5867Email kim.k.adkison@viivhealthcare.comAbstract: Dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV) are a newly approved 2-drug regimen for the treatment of HIV in virally suppressed patients. …”
Get full text

Development and initial validation of a postal survey evaluation of community pharmacists’ opinion regarding falsified (counterfeit) medicines in Hampshire (UK) by Ravina Barrett, Hussein A. Al-Mousawi

“…Context: Falsified-medicines pose a worldwide problem to patients, healthcare professionals, pharmaceutical companies, and governments. Community pharmacists are usually the last points of contact with patients and can protect them by quarantining falsified medicines. …”
Get full text

Exploring how biobanks communicate the possibility of commercial access and its associated benefits and risks in participant documents by G. Samuel, F. Hardcastle, R. Broekstra, A. Lucassen

“…Biobank resources may be accessible to researchers with commercial motivations, for example, researchers in pharmaceutical companies who may utilise the data to develop new clinical therapeutics and pharmaceutical drugs. …”
Get full text

Aluminum Adjuvant in Vaccines: A New Research Avenue is Demanded by Alberto Rubio-Casillas, Elrashdy Redwan, Vladimir N. Vuversky

“…Rather, what they have been questioning is the safety of aluminum as an adjuvant.Conclusions: The present work encourages researchers, health regulatory agencies, and even pharmaceutical companies to allow themselves to think about the possibility that aluminum-based adjuvants could be toxic for susceptible children.…”
Get full text

Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases by Anirban Sengupta, Mohammad Azharuddin, Noha Al-Otaibi, Jorma Hinkula

“…The use of nanoparticles for developing vaccines has become a routine process for researchers and pharmaceutical companies. Gold nanoparticles (GNPs) are chemical inert, have low toxicity, and are easy to modify and functionalize, making them an attractive choice for nanovaccine development. …”
Get full text

Compilation of a Near-Infrared Library for Construction of Quantitative Models of Oral Dosage Forms for Amoxicillin and Potassium Clavulanate by Wen-bo Zou, Xiao-meng Chong, Yan Wang, Chang-qin Hu

“…The NIR spectral library of amoxicillin and potassium clavulanate ODFs was defined and comprised the spectra of 377 batches of samples produced by 26 domestic pharmaceutical companies, including tablets, dispersible tablets, chewable tablets, oral suspensions, and granules. …”
Get full text

Log-Linear Model and Multistate Model to Assess the Rate of Fibrosis in Patients With NAFLD by Iman M. Attia

“…In addition, this analysis can be used by pharmaceutical companies to conduct longitudinal studies to assess the effectiveness of the newly emerging anti-fibrotic drugs.…”
Get full text

Analysis of cephalosporins available in India: A pharmacoeconomic perspective by Ritesh Churihar, Hemant Tanwani, Kamayani Gupta

“…Cost of drugs (may be generic or commercial or of different formulations) was obtained from latest periodic manuals of Indian Drug Review (INR) and drug today and was analyzed for cost ratio, cost range, and percentage difference among brands from different pharmaceutical companies for oral and parental forms. Correlation among price variations between them was observed by data comparison. …”
Get full text